Clinical Trials in Wolverhampton, United Kingdom
62 recruiting
Showing 1–20 of 72 trials
Recruiting
Phase 3
ROSETTA Breast-01: The Effects and Safety of Pumitamig in Patients With Triple-Negative Breast Cancer
Breast Neoplasms
BioNTech SE558 enrolled83 locationsNCT07173751
Recruiting
Phase 2Phase 3
Combined Dose-Finding and CV Outcomes Study With CSL300 (Clazakizumab) in Adult Subjects With ESKD Undergoing Dialysis
Atherosclerotic Cardiovascular Disease
CSL Behring2,310 enrolled542 locationsNCT05485961
Recruiting
Phase 3
A Phase 3 Study to Evaluate the Safety and Efficacy of KarXT + KarX-EC for the Treatment of Agitation Associated With Alzheimer's Disease (ADAGIO-2)
Alzheimer Disease
Bristol-Myers Squibb352 enrolled140 locationsNCT07011745
Recruiting
Phase 3
Seladelpar in Subjects With Primary Biliary Cholangitis (PBC) and Compensated Cirrhosis
Primary Biliary Cholangitis
Gilead Sciences318 enrolled196 locationsNCT06051617
Recruiting
A Study in Participants With Active Systemic Lupus Erythematosus With Inadequate Response to Glucocorticoids and ≥2 Immunosuppressants
Systemic Lupus Erythematosus (SLE)
Bristol-Myers Squibb223 enrolled54 locationsNCT07175285
Recruiting
Phase 3
MITHRIDATE: Ruxolitinib Versus Hydroxycarbamide or Interferon as First Line Therapy in High Risk Polycythemia Vera
Polycythemia Vera
University of Birmingham586 enrolled47 locationsNCT04116502
Recruiting
The Biomechanical Outcomes of Autologous Chondrocyte Implantation
Chondral Defect
University of Manchester47 enrolled7 locationsNCT06921889
Recruiting
Phase 3
Extension Study for the Port Delivery System With Ranibizumab (Portal)
Hoffmann-La Roche1,000 enrolled165 locationsNCT03683251
Recruiting
Phase 3
Long-term Safety and Efficacy Extension Study for Participants With Advanced Tumors Who Are Currently on Treatment or in Follow-up in a Pembrolizumab (MK-3475) Study (MK-3475-587/KEYNOTE-587)
Solid TumorsHematologic Malignancies
Merck Sharp & Dohme LLC3,500 enrolled779 locationsNCT03486873
Recruiting
Phase 2Phase 3
Evaluation of Efficacy, Safety, and Tolerability of Povetacicept in Participants With Primary Membranous Nephropathy (pMN)
Primary Membranous Nephropathy
Vertex Pharmaceuticals Incorporated176 enrolled86 locationsNCT07204275
Recruiting
Not Applicable
WithHolding Enteral Feeds Around Blood Transfusion (International)
Necrotizing Enterocolitis
IWK Health Centre4,333 enrolled40 locationsNCT05213806
Recruiting
Phase 3
MagnetisMM-32: A Study to Learn About the Study Medicine Called Elranatamab in People With Multiple Myeloma (MM) That Has Come Back After Taking Other Treatments (Including Prior Treatment With an Anti-CD38 Antibody and Lenalidomide)
Multiple Myeloma
Pfizer492 enrolled274 locationsNCT06152575
Recruiting
Phase 3
A Study to Investigate the Efficacy and Safety of Anifrolumab Administered as Subcutaneous Injection and Added to Standard of Care Compared With Placebo Added to Standard of Care in Adult Participants With Idiopathic Inflammatory Myopathies (Polymyositis and Dermatomyositis)
Polymyositis, Dermatomyositis
AstraZeneca240 enrolled234 locationsNCT06455449
Recruiting
Phase 3
A Study to Evaluate the Long-term Efficacy and Safety of KarXT + KarX-EC for Agitation in Alzheimer's Disease (ADAGIO-3)
Alzheimer DiseaseAgitation
Bristol-Myers Squibb600 enrolled241 locationsNCT06937229
Recruiting
Phase 2
A Study of Brenipatide in Participants With Opioid Use Disorder
Eli Lilly and Company465 enrolled57 locationsNCT07420283
Recruiting
Phase 3
A Study of First-Line Olomorasib (LY3537982) and Pembrolizumab With or Without Chemotherapy in Patients With Advanced KRAS G12C-Mutant Non-small Cell Lung Cancer
Eli Lilly and Company1,264 enrolled422 locationsNCT06119581
Recruiting
Phase 3
A Study of Belantamab Mafodotin Administered in Combination With Lenalidomide and Dexamethasone (BRd) Versus Daratumumab, Lenalidomide, and Dexamethasone (DRd) in Participants With Newly Diagnosed Multiple Myeloma (NDMM) Who Are Ineligible for Autologous Stem Cell Transplantation (TI-NDMM)
Multiple MyelomaNewly Diagnosed Multiple Myeloma
GlaxoSmithKline520 enrolled181 locationsNCT06679101
Recruiting
Phase 3
Zilebesiran in Patients With Hypertension Not Adequately Controlled and With Either Established Cardiovascular Disease or High Risk for Cardiovascular Disease
HypertensionHigh Risk Cardiovascular DiseaseHigh Cardiovascular Risk
Alnylam Pharmaceuticals11,000 enrolled597 locationsNCT07181109
Recruiting
Not Applicable
The Clinical Utility of BioEP in Diagnostic Decision Making in Epilepsy
Epilepsy
Neuronostics Ltd559 enrolled2 locationsNCT06097195
Recruiting
Phase 3
A Study to Evaluate the Efficacy of Pumitamig Versus Pembrolizumab in Participants With Previously Untreated Advanced Non-Small Cell Lung Cancer and PD-L1 ≥ 50%. (ROSETTA Lung-202)
Bristol-Myers Squibb750 enrolled271 locationsNCT07361510